Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-275291 + carboplatin + paclitaxel
- Development stage
- Preclinical
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a combination therapy consisting of BMS-275291 (rebimastat), carboplatin, and paclitaxel. BMS-275291 is an orally administered, broad-spectrum matrix metalloproteinase inhibitor (MMPI) developed to inhibit tumor growth and metastasis by blocking the activity of matrix metalloproteinases involved in extracellular matrix degradation. Unlike earlier MMPIs, it was designed to avoid dose-limiting joint toxicity. Carboplatin is a platinum-based chemotherapeutic agent that induces DNA crosslinking and apoptosis in cancer cells. Paclitaxel is a microtubule-stabilizing agent that inhibits cell division by preventing microtubule depolymerization. This combination was investigated primarily for advanced non-small-cell lung cancer (NSCLC). Clinical trials found that adding BMS-275291 to standard chemotherapy with carboplatin and paclitaxel increased toxicity without improving survival outcomes in NSCLC patients[1][3][4].
- Other names
- rebimastat + carboplatin + paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))MMP12 (Macrophage Metalloelastase)DNA
Beyond the preview
Go deeper on BMS-275291 + carboplatin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-275291 + carboplatin + paclitaxel.